The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of parkinson's disease: A review

International Journal of Neuroscience

Volumn 121, Issue 2, 2011, Pages 51-57

  De Araújo, Dayane Pessoa ^a   Lobato, Rodrigo De Freitas Guimarães ^a   Cavalcanti, José Rodolfo Lopes De Paiva ^b   Sampaio, Luis Rafael Leite ^a   Araújo, Paulo Victor Pontes ^a   Silva, Marcia Calheiros Chaves ^a   Neves, Kelly Rose Tavares ^a   Fonteles, Marta Maria De França ^a   Sousa, Francisca Clea Florenço De ^a   Vasconcelos, Silvania Maria Mendes ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b DEPARTAMENTO DE FÍSICA   (Brazil)

Author keywords

Acid lipoic; Antioxidant; Neuroprotective; Oxidative stress; Parkinson's disease; Treatment

Indexed keywords

ACETYLCHOLINE; AMINE OXIDASE (FLAVIN CONTAINING); ASCORBIC ACID; CYCLOOXYGENASE 1; CYTOCHROME C; DOPAMINE; GAMMA INTERFERON; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; REACTIVE OXYGEN METABOLITE; THIOCTIC ACID; TOCOPHEROL; TUMOR NECROSIS FACTOR ALPHA;

ACETYLCHOLINE BRAIN LEVEL; ANTIOXIDANT ACTIVITY; APOPTOSIS; BASAL GANGLION; BLOOD BRAIN BARRIER; CELL INCLUSION; CENTRAL NERVOUS SYSTEM; CORPUS STRIATUM; CYTOKINE RESPONSE; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG STRUCTURE; GLIA CELL; GLOBUS PALLIDUS; HUMAN; IMMUNE SYSTEM; LEWY BODY; MICROGLIA; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROPROTECTION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; REVIEW; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; DISEASE PROGRESSION; HUMANS; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; THIOCTIC ACID;

EID: 78651081142     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2010.535934     Document Type: Review

References (74)

1. Aguiar, L. M., Macêdo, D. S., Vasconcelos, S. M., Oliveira, A. A., Sousa, F. C., & Viana, G. S. (2008). CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats. Brain Research, 1191(2), 192-199.
2. Aguiar, L.M., Nobre, H.V.,Macedo, D. S., Oliveira, A.A., Freitas, R. M., Vasconcelos, S. M., et al. (2006). Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacology Biochemistry and Behaviour, 84(3), 415-419.
3. Balamurugan, K., Vazirim, N. D., & Said, H. M. (2005). Biotin uptake by human proximal tubular epithelial cells: Cellular and molecular aspects. American Journal of Physiology. Renal Physiology, 288(4), 823-831.
4. Barbosa, M. T., Caramelli, P., Maia, D. P., Cunningham, M. C. Q., Guerra, H. L., & Lima, C. M. F. (2006). Parkinsonism and Parkinsons disease in the elderly: A community-based survey in Brazil (the Bambui study). Movement and Disorder, 21(6), 800-808.
5. Barsottini, O. G. P. (2009). Parkinsons disease: Molecular and imaging characteristics. Arquivos de Neuropsiquiartia, 67(1), 7-11.
6. Bear, M. F., Connors, B. W., & Paradiso, M. A. (2002). Neuroscience: Finding the Nervous System., 2nd edn. Porto Alegre: ArtMed.
7. Biewenga, G. P., Haenen, G. R.M. M., & Bast, A. (2000). The pharmacology of the antioxidante lipoic acid. General Pharmacology, 29(3), 315-331.
8. Bilska, A., Dubiel, M., Sokolowska-Jezewicz, M., Lorenc-koci, E., & Wlodek, L. (2007). Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex of rat brain. Neuroscience, 146(4), 1758-1771.
9. Bist, R., & Bhatt,D. K. (2009). The evaluation of effect of alpha-lipoic acid and vitamin E on the lipid peroxidation, gamma-amino butyric and serotonin level in the brain of mice (Mus musculus) acutely intoxicated with lindane. Journal of the Neurology Science, 276(1-2), 99-102.
10. Bist, R., & Bhatt, D. K. (2010). Augmentation of cholinesterases and ATPase activities in the cerebellum and pons-medulla oblongata, by a combination of antioxidants (resveratrol, ascorbic acid, alpha-lipoic acid and vitamin E), in acutely lindane intoxicated mice. Journal of Neurological Sciences, 296(1-2), 83-87.
11. Brazil. (2006). Ministry of Health, Department of Health Policy Epidemiological Bulletin. Brasilia: Ministry of Health.
12. Calxeta, L., & Vieira, R. T. (2008). Dementia in Parkinsons disease. Revista Brasileira de Psiquiatria, 30(4), 375-383.
13. Chen, J. F. (2003). The adenosine A(2A) receptor as an attractive target for Parkinsons disease treatment. Drug News & Perspectives, 16(9), 597-604.
14. Chng, H. T., New, L. S., Neo, A. H., Goh, C. W., Browne, E. R., & Chan, E. C. Y. (2009). Distribution study of orally administered lipoic acid in rat brain tissues. Brain Research, 1251(2), 80-86.
15. Cross, A. K., & Woodroofe, M. N. (2001). Immunoregulation of microglial functional properties. Microscopy Research and Technique, 54, 10-17.
16. Dauer, W., & Przedborski, S. (2003). Parkinsons disease: Mechanisms and models. Neuronscience, 39(2), 889-909.
17. Dietrichs, E. (2008). Bevegelsesforstyrrelser og basalganglienes funksjon. Tidsskr Nor Legeforen, 128(17), 1968-1971.
18. Di Stefano, A., Sozio, P., Cerasa, L. S., Iannitelli, A., Cataldi, A., Zara, S., et al. (2010). Ibuprofen and lipoic acid diamide as codrug with neuroprotective activity: Pharmacological properties and effects in beta-amyloid (1-40) infused Alzheimers disease rat model. International Journal of Immunopathology and Pharmacology, 23(2), 589-599.
19. Eberhardt, O., & Schulz, J. B. (2003). Apoptotic mechanism and antiapoptotic therapy in the MPTP model. Toxicology Letters, 139(2-3), 135-151.
20. Ferreira, I. C. R. F., & Abreu, R. M. V. (2007). Oxidative stress, antioxidants and phytochemicals. Bioanálise, 4(2), 12-18
21. Ferreira, P. M. P., Militão, C. G. C., & Freitas, R. M. (2009). Lipoic acid effects on lipid peroxidation level, superoxide dismutase activity and monoamines concentration in rat hippocampus. Neuroscience Letters, 464(2), 131-134.
22. Freinbichler, W., Bianchi, L., Colivicchi, M. A., Ballini, C., Tipton, K. F., Linert,W., et al. (2008). The detection of hydroxyl radicals in vivo. Journal of Inorganic Biochemistry, 102(5-6), 1329-1333.
23. Freitas, R. M. (2009). Pharmacological studies of lipoic acid on behavioral changes and activity of superoxide dismutase in the striatum of rats after seizures induced by pilocarpine. Revista Eletrônica de Farmácia, 6(1), 65-72.
24. Freitas, R. M., Gomes, K. N., & Saldanha, G. B. (2010). Neuropharmacological effects of lipoic acid and ubiquinone on the mRNA level of interleukin-1beta and acetylcholinesterase activity in rat hippocampus after seizures. Fundamental & Clinical Pharmacology, 6(3), 80-86.
25. Freitas, R. M., Oliveira, S. F., Saldanha, G. B., & Jordán, J. (2010). Lipoic acid alters amino acid neurotransmitters content in rat hippocampus after pilocarpine-induced seizures. Fundamental& Clinical Pharmacology, 6(3), 67-75.
26. Godeiro Júnior, C.O., Aguiar, P. M. C., Fełcio, A. C., & Ferraz, H. B. (2007).Mitoc ôndria e doença de Parkinson: Contribuiç ões da genética no conhecimento do processo patogênico. Einstein, 5(2), 177-181.
27. Hald, A., & Lotharius, J. (2005). Oxidative stress and inflammation in Parkinsons disease: Is there a causal link? Experimental Neurology, 193(3), 279-290.
28. Han, B. S., Hong, H. S., Choi, W. S., Markelonis, G. J., Oh, T. H., & Oh, Y. J. (2003). Caspase-dependent and -independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment. Journal Neuroscience, 23(3), 5069-5078.
29. Hanrott, K., Gudmunsen, L., Oneill, M. J., & Wonnacott, S. (2006). 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. Journal of Biological Chemistry, 281(9), 5373-5382.
30. Hirsch, E. C., Hunot, S., & Hartmann, A. (2005). Neuroinflammatory processes in Parkinsons disease. Parkinsonism&Related Disorders, 11(1), 9-15.
31. Ionov, I. D. (2008). Self-amplification of nigral degeneration in Parkinsons disease: A hypothesis. International Journal of Neuroscience, 118(2), 1741-1758.
32. Jarrett, S. G. (2008). Mitochondrial DNA damage and impaired base excision repair during epileptogenesis. Neurobiology Disorders, 30(1), 130-138.
33. Kandel, E. R., Schwartz, J. H., & Jessel, T. M. (2003). Principles of Neuroscience. São Paulo: Manole.
34. Kulich, S. M., & Chu, C. T. (2003). Role of reactive oxygen species in extracellular signal-regulated protein kinase phosphorylation and6-hydroxydopamine cytotoxicity. Journal of Biosciences, 28(2), 83-89.
35. Kunt, T., Forst, T., Wilhelm, A., Tritschler, A., Pfuetzner, A., & Harzer,O. (1999). Alpha-lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end products. Clinical Science, 96(4),75-82.
36. Leist, M., & Jaattela,M. (2001). Four deaths and a funeral: From caspases to alternative mechanisms. Nature Reviews. Molecular Cell Biology, 2(3), 589-598
37. Lima, R.M., Costa, A. M. R., Souza, R. N., & Gomes, L. W. (2007). Inflamaç ão em doenças neurodegenerativas. Revista Para Medicina, 21(2), 5-9.
38. Machado, A. (2006). Functional Neuroanatomy. São Paulo: Atheneu
39. Maczurek, A., Hager, K., Kenklies, M., Sharman, M., Martins, R., Engel, J., et al. (2008). Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimers disease. Advanced Drug Delivery Reviews, 60(2), 1463-1470.
40. Martin, J. H. (1999). Neuroanatomy: Text and Atlas. Porto Alegre: Artes Médicas.
41. Melo, L. M., Barbosa, E. R., & Caramelli, P. (2007). Cognitive decline and dementia in Parkinsons disease: Clinical features and treatment. Revista de Psiquiatria Cłnica, 34(4), 176-183.
42. Mosley, R. L., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K., et al. (2006). Neuroinflammation, oxidative stress and the pathogenesis of Parkinsons disease. Clinical Neuroscience Research, 6(3), 261-281.
43. Nagatsu, T., Mogi, M., Ichinose, H., & Togari, A. (2000). Cytokines in Parkinsons disease. Journal Neural Transmition, 58(4), 143-151.
44. Nakabayashi, T. I. K., Chagas, M. H. N, Corrêa, A. C. L, Tumas, V, Loureiro, S. R, & Crippa, J. A. S. (2008). Prevalence of depression in Parkinsons disease. Revista de Psiquiatria Cłnica, 35(6), 219-227.
45. Nicholls, D. G. (2008). Oxidative stress and energy crises in neuronal dysfunction. Annals of the New York Academy of Sciences, 1147(3), 53-60.
46. Obeso, J. A., Rodriguez-oroz, M. C., Rodr̈guez, M., Lanciego, J. L., Artieda, J., Gonzalo, N., et al. (2000). Pathophysiology of the basal ganglia in Parkinsons disease. Trends Neuroscience, 23(3), 8-19.
47. Packer, L. (1999). Oxygen Club of Califórnia Annual Meeting Oxidants & Antioxidantes in Biology. San Francisco.
48. Packer, L., Tritschler, H. J., & Wessel, K. (1997). Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radical Biology & Medicine, 22(3), 359-378.
49. Packer, L., Witt, E. H., & Tritschler, H. J. (1995). Alpha-Lipoic acid as a biological antioxidant. Free Radical Biology & Medicine, 19(3), 227-250.
50. Pereira, M. C. L., Suzuki, D. E., Janjoppi, L., & Okamoto, O. K. (2007). Estratégias para neuro-restauraç ão em modelos experimentais de doença de Parkinson. Einstein, 5(4), 142-148.
51. Ravina, B.M., Fagan, S. C., Hart, R. G., Hovinga, C. A.,Murphy, D. D.,Dawson, T. M., et al. (2003).Neuroprotective agents for clinical trials in Parkinsons disease: A systematic assessment. Neurology, 60(3), 1234-1240.
52. Rodrigues, M., & Campos, L. C. (2006). Tegy for treatment with levodopa in Parkinsons disease. Revista Analytica, 5(23), 121-129.
53. Salinthone, S., Yadav, V., Bourdette, D. N., & Carr, D. W.(2008). Lipoic acid: A novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS. Endocrine, Metabolic & Immune Disorders Drug Targets, 8(2), 132-142.
54. Salvesen,G. S. (2002). Caspases and apoptosis. Essays in Biochemistry, 38(3), 9-19.
55. Santos, I. M., Freitas, R. L., Saldanha, G. B., Tomé Ada, R., Jordán, J., & Freitas, R. M. (2010). Alterations on monoamines concentration in rat hippocampus produced by lipoic acid. Arq Neuro- Psiquiatr, 68(3), 362-366.
56. Schillace, R. V., Pisenti, N., Pattamanuch, N., Galligan, S., Marracci, G. H., & Bourdette, D. N. (2007). Lipoic acid stimulates cAMP production in T lymphocytes and NK cells. Biochemical and Biophysical Research Communications, 354(3), 259-264.
57. Scotti, L., Scotti, M. T., Cardoso, C., Pauletti, P., Castro, G. I., & Bolzani, V. S. (2007). Modelagem molecular aplicada ao desenvolvimento de moléculas com atividade antioxidante visando ao uso cosmético. Brazilian Journal of Pharmaceutical Sciences, 43(2), 3-12.
58. Shay, K. P., Moreau, R. F., Smith, E. J., Smith, A. R., & Hagen, T. M. (2009). Alpha-lipoic acid as a dietary supplement:Molecular mechanisms and therapeutic potential. Biochim et Biophys Acta, 1790(2), 1149-1160.
59. Smith, A. R., Shenvi, S. V.,Widlansky,M., Suh, J. H., & Hagen, T. M. (2004). Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Current Medicinal Chemistry, 11(2), 4-12.
60. Syntichaki, P., & Tavernarakis, N. (2003). The biochemistry of neuronal necrosis: Rogue biology? Nature Reviews. Neuroscience, 4(2), 672-684.
61. Tatton, W. G., Chalmers, R. R., Brown, D., & Tatton, N.(2003). Apoptosis in Parkinsons disease: Signals for neuronal degradation. Annals of Neurology, 53(4), 61-70.
62. Teichert, J., Kern, H. J., Tritschler, H., & Ulrich, R. (2000). Preiss, Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics, 36(3), 625-628.
63. Teive, H. A.G. (2005). Etiopathogenesis of Parkinson Disease. Revista Neurociências, 13(4), 132-136.
64. Vale, O. C., Fonteles, D. S. R., Cabral, F. R., & Fonteles, M. C. (2003). A dual action of α-lipoic acid in the brain an electrophysiological evaluation. Arq Neuropsiquiatria, 61(3-B), 738-745.
65. Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. D., Mazur, M., & Telser, J. (2007). Free radicals and antioxidants in normal physiological functions and human disease. The International Journal of Biochemistry and Cell Biology, 39(3), 44-84.
66. Vila, M., Jackson, L. V., Guégan, C., Chu, W. D., Teismann, P., & Choi, D. K. (2001). The role of glial cells in Parkinsons disease. Current Opinion in Neurology, 14(4), 483-489.
67. Wang, P. G., Xian, M., Tang, X., Wu, X., Wen, Z., Cai, T., et al. (2002). Nitric oxide donors: Chemical activities and biological applications. Chemical Reviews, 102(2), 1091-1134.
68. Wang, S. J., & Chen, H. H. (2007). Presynaptic mechanisms underlying the a-lipoic acid facilitation of glutamate exocytosis in rat cerebral cortex nerve terminals. Neurochemistry International, 50(4), 51-60.
69. Weintraub, D., Comella, C.L., & Horn, S. (2008). Parkinsons disease Part 2: Treatment of motor symptoms. The American Journal of Managed Care, 14(2 Suppl), 59-69.
70. Wollin, S. D., & Jones, P. J. (2003). Alpha-lipoic acid and cardiovascular disease. Journal of Nutrition, 133(2), 3327-3330.
71. Xu, K., Bastia, E., & Schwarzschild, M. A. (2005). Therapeutic potential of adenosine A2A receptor antagonists in Parkinsons disease. Pharmacology Therapy, 105(5), 267-310.
72. Xu, K., Xu, Y. H., Chen, J. F., & Schwarzschild, M. A. (2002). Caffeines neuroprotection against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neuroscience Letters, 322(2), 3-6.
73. Zhang, H., Jia, H., Liu, J., Ao, N., Yan, B., Shen, W., et al. (2010). Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinsons disease. Journal of Cellular and Molecular Medicine, 14(1-2), 215-225.
74. Zhou, C., Huang, Y., & Przedborski, S. (2008). Oxidative stress in Parkinsons disease: A mechanism of pathogenic and therapeutic significance. Annals of the New York Academy of Sciences, 1147(3), 93-104.